RECRUITING

MS-ResearchBiomarkerS

Talk to us

Conditions

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary ProgressiveClinically Isolated SyndromeRadiologically Isolated SyndromeNeuromyelitis Optica Spectrum DisordersMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseNeurologic Autoimmune DiseaseNeurologic DisorderHealthy Aging

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.

Official Title

Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders

Quick Facts

Study Start:2021-11-11
Study Completion:2041-11-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05204459

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subjects who meet any one of the following diagnostic criteria:
  2. * Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria.
  3. * Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria.
  4. * Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease.
  5. * Diagnosis of neurological disorders other than MSRD.
  6. * Healthy volunteer.
  7. * Age ≥18.
  8. * Able to give informed consent.
  1. * Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves).
  2. * Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study.
  3. * Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT/OCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).

Contacts and Locations

Study Contact

Omar Al-Louzi, MD
CONTACT
(310) 423-4008
omar.allouzi@cshs.org
Group Neurology Research
CONTACT
(310)-423-6472
GroupNeurologyMSProgramResearch@cshs.org

Principal Investigator

Omar Al-Louzi, MD
PRINCIPAL_INVESTIGATOR
Cedars-Sinai Medical Center
Marwa Kaisey, MD
STUDY_DIRECTOR
Cedars-Sinai Medical Center
Brooke Guerrero, MD
STUDY_DIRECTOR
Cedars-Sinai Medical Center
Laura Locke, CRNP
STUDY_DIRECTOR
Cedars-Sinai Medical Center
Pascal Sati, PhD
STUDY_DIRECTOR
Cedars-Sinai Medical Center
Nancy Sicotte, MD
STUDY_CHAIR
Cedars-Sinai Medical Center

Study Locations (Sites)

Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States

Collaborators and Investigators

Sponsor: Cedars-Sinai Medical Center

  • Omar Al-Louzi, MD, PRINCIPAL_INVESTIGATOR, Cedars-Sinai Medical Center
  • Marwa Kaisey, MD, STUDY_DIRECTOR, Cedars-Sinai Medical Center
  • Brooke Guerrero, MD, STUDY_DIRECTOR, Cedars-Sinai Medical Center
  • Laura Locke, CRNP, STUDY_DIRECTOR, Cedars-Sinai Medical Center
  • Pascal Sati, PhD, STUDY_DIRECTOR, Cedars-Sinai Medical Center
  • Nancy Sicotte, MD, STUDY_CHAIR, Cedars-Sinai Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-11
Study Completion Date2041-11-11

Study Record Updates

Study Start Date2021-11-11
Study Completion Date2041-11-11

Terms related to this study

Keywords Provided by Researchers

  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Clinically Isolated Syndrome
  • Radiologically Isolated Syndrome
  • Neuromyelitis Optica Spectrum Disorders
  • Myelin oligodendrocyte glycoprotein antibody-associated disease
  • Neurologic Autoimmune Disease
  • Neurologic Disorder
  • Healthy Aging

Additional Relevant MeSH Terms

  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Clinically Isolated Syndrome
  • Radiologically Isolated Syndrome
  • Neuromyelitis Optica Spectrum Disorders
  • Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
  • Neurologic Autoimmune Disease
  • Neurologic Disorder
  • Healthy Aging